Clinical trials: sponsored by Gan & Lee Pharmaceuticals.
- Lead sponsor (exact) Gan & Lee Pharmaceuticals.
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Atopic Dermatitis
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a…
- Trial name
- NCT07920783
- Testing
- GLR2053 Tablets
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Healthy Participants
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of…
- Trial name
- NCT07918898
- Testing
- GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Hypoalbuminemia in Cirrhotic Ascites
A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia
This trial is conducted in China. This study plans to include 3 parts,Part A, a single ascending dose (SAD) study in healthy trial participants; Part B, a multiple dose (MD) study in healthy trial participants; and Part C, a…
- Trial name
- NCT07851688
- Testing
- Human Serum Albumin(HSA), GLR1075 Injection
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
T2D
Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
This study is a single-center, open-label, randomized, single-dose bioequivalence trial conducted in healthy adult participants.
- Trial name
- NCT07670897
- Testing
- GZR4 injection A, GZR4 injection B
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity&T2D
Bioequivalence Study of GZR18 Injection Before and After CMC Change
This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects.
- Trial name
- NCT07355738
- Testing
- GZR18 injection A, GZR18 injection B
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Biosimilarity
A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects
This is a randomized, double-blind, single-dose, parallel comparison biosimilarity study conducted in healthy Chinese adult male subjects. It is planned to enroll 198 male subjects in this study.
- Trial name
- NCT07334496
- Testing
- GLR1044 injection, Dupilumab Injection
- Where
- China
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.
- Trial name
- NCT07193147
- Testing
- GZR4
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity/Overweight
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal liver function and those with mild, moderate or…
- Trial name
- NCT07144098
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.